Spots Global Cancer Trial Database for Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Study Description

Brief Summary: Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.

Detailed Description: Primary Objectives: I. To correlate tumor vascular permeability by DCE-MRI with clinical outcome for patients treated with sunitinib (PFS). II. To correlate genetic and histologic characteristics of the primary tumor with vascular permeability by DCE-MRI. Secondary Objectives: I. To correlate genetic and histologic characteristics of the primary tumor with clinical outcome for patients treated with sunitinib. II. Samples will be collected for potential future exploratory analyses of pharmacokinetic and pharmacogenomic parameters. Outline: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial